Israeli biotechnology company NeuroSense Therapeutics Ltd (Nasdaq: NRSN) announced on Tuesday a further update on its plans to file for early commercialisation approval for PrimeC under Health Canada's Notice of Compliance with Conditions (NOC/c) policy.
The submission is based on promising results from the company's Phase 2b ALS PARADIGM clinical trial, supported by additional clinical and preclinical data.
Dossier submission is planned for the second quarter of 2025, with a regulatory decision expected by the first quarter of 2026.
This decision follows the recommendations of Canadian regulatory experts and recent clinical findings, which demonstrated that PrimeC significantly reduced disease progression and improved survival rates by 43% compared to placebo, highlighting its potential as a breakthrough therapy for ALS.
NeuroSense anticipates a significant market opportunity in Canada, with potential peak annual revenue of USD100m to USD150m, driven by the prevalence of ALS in Canada, estimated market penetration of PrimeC, estimated price, and the current unmet demand for effective ALS treatments. After Canada, the company is planning to pursue regulatory approval in additional global markets.
Sanofi commits USD18m to boost diversity in clinical studies
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
Saniona reaches milestone in Boehringer Ingelheim partnership
Lipella granted patent for innovative drug delivery technology
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
PharmAbcine's PMC-403 Phase one clinical trial single ascending dose cohort receives safety approval
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline